Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.68 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.54 |
| ▸ | GNPAT | O15228 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343100 | 1.00 | SLC6A5 (0.68) | SLC6A5FOLH1NOD1ITGB3ITGA2B | |
| SCHEMBL9716812 | 0.95 | SLC6A5 (0.62) | SLC6A5FOLH1NOD1ITGB3ITGA2B | |
| SCHEMBL9716672 | 0.95 | SLC6A5 (0.62) | SLC6A5FOLH1NOD1ITGB3ITGA2B | |
| SCHEMBL9716666 | 0.95 | SLC6A5 (0.62) | SLC6A5FOLH1NOD1ITGB3ITGA2B | |
| SCHEMBL341587 | 0.92 | SLC6A5 (0.75) | SLC6A5FOLH1NOD1ITGB3ITGA2B | |
| SCHEMBL28183786 | 0.92 | SLC6A5 (0.75) | SLC6A5FOLH1NOD1ITGB3ITGA2B | |
| SCHEMBL341123 | 0.90 | SLC6A5 (0.82) | SLC6A5FOLH1NOD1ITGB3ITGA2B | |
| SCHEMBL1043507 | 0.90 | SLC6A5 (0.82) | SLC6A5FOLH1NOD1ITGB3ITGA2B | |
| SCHEMBL342965 | 0.89 | SLC6A5 (0.85) | SLC6A5FOLH1NOD1ITGB3ITGA2B | |
| SCHEMBL9716727 | 0.89 | SLC6A5 (0.85) | SLC6A5FOLH1NOD1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080241862-A1 | PROPIONYL AND BUTYRYL LYSINE MODIFICATIONS IN PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2008-10-02 | — | — | US | claimed |
| US-20250388638-A1 | COMPOSITIONS AND METHODS FOR ORAL DELIVERY | IMAGINE PHARMA LLC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12371817-B2 | Methods of making and utilizing amber-obligated phage display libraries | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2025-07-29 | — | — | US | disclosed |
| CN-113785058-B | Methods of making and using amber-specific phage display libraries | 得克萨斯A&M大学系统 | 2024-12-24 | — | — | CN | disclosed |
| EP-4444352-A1 | COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION | IMAGINE PHARMA, LLC (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118613284-A | Compositions and methods for oral administration | 想象制药有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20240269106-A1 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | COUNCIL OF SCIENT AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN (IN) | 2024-08-15 | — | — | US | disclosed |
| WO-2023108126-A9 | COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION | IMAGINE PHARMA LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023108126-A1 | COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION | IMAGINE PHARMA LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022254465-A1 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2022-12-08 | — | — | WO | disclosed |
| EP-0705279-B1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORP (US) | 2003-02-19 | — | — | EP | disclosed |
| US-6090912-A | MULTIPLICITY OF SEPARATE SOLID SUPPORTS WITH SURFACE HAVING SUCEPTIBLE LINKER TO SINGLE SPECIES OF TEST COMPOUND AND WITH INTERIOR HAVING ATTACHED NON-CLEAVABLE CODING MOLECULE; FOR SCREENING LIGANDS OR ACCEPTORS | SELECTIDE CORPORATION (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0705279-A4 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORP (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5840485-A | SYNTHETIC TEST COMPOUNDS ATTACHED TO SEPARATE PHASE SYNTHESIS SUPPORTS THAT ALSO CONTAIN CODING MOLECULES THAT ENCODE THE STRUCTURE OF THE SYNTHETIC TEST COMPOUND | SELECTIDE CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0705279-A1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORPORATION (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1994028028-A1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
| EP-0173960-A2 | Muramylpeptide active ester derivatives | Hamaoka, Toshiyuki (JP) | 1986-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388638-A1 | COMPOSITIONS AND METHODS FOR ORAL DELIVERY | VIP, FABP2, IGFBP1 | SLC6A5 2383/4885FOLH1 288/4885NOD1 2429/4885 |
| US-20240269106-A1 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | EP300, HDAC1, HDAC3 | SLC6A5 4862/4885FOLH1 4775/4885NOD1 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.